Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment)
EM Krieger, LF Drager, DMA Giorgi, AC Pereira… - …, 2018 - Am Heart Assoc
The aim of this study is to compare spironolactone versus clonidine as the fourth drug in
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy
adherence was checked by pill counting. Patients with resistant hypertension (no office and
ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including
a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with
spironolactone (12.5–50 mg QD) or clonidine (0.1–0.3 mg BID). The primary end point was …
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy
adherence was checked by pill counting. Patients with resistant hypertension (no office and
ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including
a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with
spironolactone (12.5–50 mg QD) or clonidine (0.1–0.3 mg BID). The primary end point was …
Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension
AC Guimarães, EM Krieger, LF Drager, D Giorgi… - 2018 - repositorio.bahiana.edu.br
The aim of this study is to compare spironolactone versus clonidine as the fourth drug in
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy
adherence was checked by pill counting. Patients with resistant hypertension (no office and
ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including
a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with
spironolactone (12.5–50 mg QD) or clonidine (0.1–0.3 mg BID). The primary end point was …
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy
adherence was checked by pill counting. Patients with resistant hypertension (no office and
ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including
a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with
spironolactone (12.5–50 mg QD) or clonidine (0.1–0.3 mg BID). The primary end point was …
以上显示的是最相近的搜索结果。 查看全部搜索结果